http://www.fpnotebook.com/
Clostridium difficileAka: Pseudomembranous colitis
- See Also
- Epidemiology
- Dramatic increase in cases in last decade
- Pathophysiology
- Anaerobic, Gram Positive, spore-forming bacillus
- New virulent strain: B1 NAP1
- Toxin A/B levels are >16 fold higher than other strains
- Sequence of infection
- Normal colonic bacteria disturbed (e.g. antibiotics)
- Exposure to C. difficile
- C. difficile is commensal in only 3% of patients
- C. difficile survives in hospital room >40 days
- Occurs in 50% of those hospitalized >4 weeks
- Colonization with Clostridium difficile
- Results in carrier state (asymptomatic) or
- Mild Diarrheal illness or
- Severe illness (pseudomembranous colitis)
- Risk Factors
- Highest risk patients
- Elderly
- Debilitated patients
- Immunocompromised patients
- Cystic Fibrosis patients (high risk for fulminant infection)
- Proton Pump Inhibitors (raise gastric pH)
- Corticosteroid use
- Recent antibiotic use
- General
- All antibiotics can cause C. difficile Diarrhea
- Broad-spectrum agents are highest risk
- Most common antibiotic causes
- Quinolones (e.g. Ciprofloxacin, Levofloxacin)
- Emerging as very common cause
- Ampicillin or Amoxicillin
- Cephalosporins
- Clindamycin
- Less common now due to decreased Clindamycin usage
- Quinolones (e.g. Ciprofloxacin, Levofloxacin)
- Less common antibiotic causes
- Macrolides (e.g. Erythromycin, Azithromycin)
- Tetracyclines antibiotics (e.g. Doxycycline)
- Sulfonamides (e.g. Bactrim)
- Trimethroprim
- Rare antibiotic causes
- Parenteral Aminoglycosides
- Metronidazole (used for treatment)
- Vancomycin (used for treatment)
- General
- Highest risk patients
- Symptoms
- Asymptomatic carrier state is common
- Diarrhea (variably present)
- Timing
- Incubates for 2-7 days after colonization
- Most cases occur on days 4-9 of antibiotic course
- Onset <14 days after antibiotics in 96% of cases
- All cases occur within 3 months of antibiotics
- Olson (1994) Infect Control Hosp Epidemiol 15:371
- Characteristics
- Frequent, loose Bowel Movements
- Mucus and occult blood often present
- Crampy Abdominal Pain
- Associated findings
- Fever
- Asymmetric oligoarticular large joint arthralgia
- Timing
- Labs
- Complete Blood Count
- Leukocytosis variably present
- Complete Blood Count
- Radiology: Abdominal XRay
- Dilated colon: >7 cm in greatest diameter
- Small bowel dilation or air-fluid levels may be present
- Mucosal edema or thumbprinting may also be present
- Diagnosis
- Clostridium difficile Toxin
- Endoscopy (Flexible Sigmoidoscopy or Colonoscopy)
- Not recommended in most cases
- May be indicated if diagnosis is unclear
- Findings: Mucosal lesions with pseudomembranes
- Differential Diagnosis
- Antibiotic intolerance (resolves off antibiotics)
- Infectious enteritis
- Acute Gastroenteritis
- Amebic dysentary
- Inflammatory Bowel Disease
- Ischemic colitis
- Management: General Measures
- Discontinue antibiotic
- Diarrhea resolves in up to 25% of cases with stopping
- If antibiotic required, choose one with lower risk
- Indications to start antibiotics immediately (empiric)
- Older patients
- Multiple comorbid conditions
- Antibiotics can not be discontinued
- Severe disease
- Persistent Diarrhea
- Dysentary (fever, Leukocytosis)
- Avoid medications that could worsen condition
- Opioid
- Antidiarrheal agents
- Do not retest for toxin post-treatment if asymptomatic
- May be positive, but does not require treatment
- Discontinue antibiotic
- Management: Adults
- Metronidazole
- Drug of choice due to low cost and high risk
- However resistance is growing and may approach 30% in some regions
- Dose
- Typical: 500 mg orally three times daily for 10-14 days
- Lower dose: 250 mg orally q6 hours for 10-14 days
- Parenteral dose: 500 mg IV q8 hours for 10-14 days
- Drug of choice due to low cost and high risk
- Vancomycin
- Precaution: Only effective for C. Difficile if dosed orally
- Indications
- Patients at high risk of fulminant disease
- Second line agent to Metronidazole
- Risk of promoting Vancomycin resistance
- Very expensive ($800 per course)
- Inexpensive if pharmacist compounds the intravenous form into oral formulation
- Dose: 125-500 mg PO qid for 10-14 days
- Use low dose (125 mg) in most patients
- Use high dose (500 mg) in severe illness
- Metronidazole
- Management: Child
- Mild to Moderate disease: Metronidazole (Flagyl)
- Metronidazole 7 mg/kg (maximum 500 mg) tid for 7 days
- Severe disease: Vancomycin
- Vancomycin 5 mg/kg (maximum 125 mg) q6 hours x7 days
- Mild to Moderate disease: Metronidazole (Flagyl)
- Management: Recurrence
- Recurrence risk doubles with each episode
- Initial recurrence risk is 20%
- After third episode, recurrence is virtually assured
- Vancomycin taper
- Starting dose 125 mg every 6 hours for 1 week
- Taper to 125 mg every 12 hours for 1 week
- Taper to 125 mg daily for 1 week
- Taper to 125 mg every other day for 1 week
- Taper to 125 mg every third day for 2 weeks
- Probiotics (e.g. Florastor)
- Saccharomyces boulardii (avoid if immunocompromised)
- Dose 250 mg PO bid to tid for 1 month
- Has also been used with Vancomycin 500 mg PO qid
- Saccharomyces boulardii (avoid if immunocompromised)
- Fecal transfer
- Healthy donor (e.g. spouse) with normal fecal flora
- Sample typically introduced via rectal enema
- Small volume fecal amount (25 grams) sufficient to reestablish normal flora
- Recurrence risk doubles with each episode
- Management: Fulminant disease (high mortality rate)
- Metronidazole IV 500 mg every 8 hours and
- Vancomycin 500 mg PO qid and
- Vancomycin enema 500 mg in 100 cc NS q6 hours
- Delivered by foley in rectum, 30 cc balloon
- Balloon inflated for 60 minutes after dose
- Prognosis: Findings of improvement (assess on day 5)
- Complications
- Toxic Megacolon
- Bowel perforation
- Dehydration or electrolyte abnormality
- Prevention
- Avoid broad-spectrum antibiotic use
- Probiotics may be considered in recurrent cases
- Prevent Clostridium difficile spore spread
- Spores are resistant to Alcohol, antibiotics and antiseptics
- Practice good hygiene
- Hand washing
- Disinfect surfaces
- Bleach
- Alkaline glutaraldehyde
- Ethylene oxide
- References
- Suntharam (2006) First 24 hours, Park Nicollet Lecture
- Jabbar (2003) Prim Care 30(1):63
- Kyne (2001) Gastroenterol Clin North Am 30(3):753
- Schroeder (2005) Am Fam Physician 71(5):921
Clostridium difficile (bacteria) (C0079134) | |
|---|---|
| Definition (CSP) | causes antibiotic-induced diarrhea or pseudomembranous colitis in humans; found in the colonic flora in 3% of healthy adults. |
| Definition (MSH) | A common inhabitant of the colon flora in human infants and sometimes in adults. It produces a toxin that causes pseudomembranous enterocolitis (ENTEROCOLITIS, PSEUDOMEMBRANOUS) in patients receiving antibiotic therapy. |
| Concepts | Bacterium (T007) |
| MSH | D016360 |
| English | Bacillus difficilis, Clostridium difficile, Clostridium difficilis |
| Parent Concepts | Clostridium (C0009054) |
| Sources | CSP, LNC, MSH, MTH, NCBI, SCTSPA, SNOMEDCT Derived from the NIH UMLS (Unified Medical Language System) |
